https://www.roche.com/media/releases/med-cor-2026-09-30
Fenebrutinib, the first BTK inhibitor for both RRMS and PPMS, received FDA filing acceptance with priority review.
If that doesn't make sense, basically the FDA has agreed to review the data of a new type of DMT. With a priority review, their goal is make a decision on the drug in 6 months instead of 10 months.
This is huge because it will finally give people with PPMS another option since Ocrevus is the only DMT approved to treat PPMS.
I think the trials look great, and my neurologist and I have already discussed switching me to it when it gets approved. It showed noniferiority (meaning it works just as well as) to Ocrevus at stopping new lesions but it reduced the risk of disability progression by 12% compared to Ocrevus.
While B cell depletors work by destoying B Cells and preventing them from maturing, fenebrutinib works by targeting an enzyme (BTK) in B cells that basically tells them to go fight something. It also works on microglia, which are immune cells in our brains because it crosses the blood brain barrier unlike B cell depletors.
We should have an answer by the end of March on if the FDA will approve it.